About Us

What began as two families fighting for their daughters’ futures has grown into a coordinated effort to change what is possible for children with de novo SPG4.

In just over two years, we have brought together families, scientists, and industry leaders to move this work forward. We’ve hosted scientific symposia in partnership with NIH and Boston Children’s Hospital, built a global network of families, and funded research initiatives that are now advancing toward clinical translation. And our community is growing alongside the science. Recent events have brought together hundreds of supporters and raised critical funding to accelerate research.

Today, The Lilly and Blair Foundation is a driving force in childhood-onset SPG4 research, funding, and advocacy.

Our Mission
Our mission is to accelerate progress toward treatments for childhood-onset, de novo SPG4 by funding critical research, connecting the right people, and driving the work needed to move from discovery to real-world impact.

The Faces of Childhood-Onset, De Novo SPG4

We are Not Just Raising Awareness.
We are Driving Progress.

The Lilly and Blair Foundation is the only nonprofit solely focused on de novo SPG4. We fund research others haven’t yet explored, move quickly, and connect families with the scientists shaping what comes next.

People are turning to us — not just for our story, but for our strategy.

  • July 2024 - Provided $150,000 in funding to Boston Children’s Hospital, UMass Chan Medical Center and the University of Wisconsin to be used toward the first 3 aims of the AAV9 Vector Gene Therapy Project for SPG4

  • November 2024 – Participated in the UltraGenyx Rare Disease Bootcamp, held in Novato, CA.

  • December 2024 - Hosted the 3rd Annual Scientific Symposium on SPG4 with Boston Children’s Hospital

  • February 2025 - Funded The Baas Lab at Drexel University to help them continue exploring ways to restore lost function in children already experiencing symptoms

  • March 2025 - Funded the Liang Lab at Drexel University to help them continue their research on SPG4 patient-derived hiPSC models.

  • March 2025 - Invited to speak at the Annual Meeting of TreatHSP and the Tom Wahlig Foundation. View the agenda here.

  • May 2025 - Hosted our third annual Golf Tournament and Dinner raising $110,000 for childhood-onset SPG4. View photos and remarks.

  • October 2025 - Hosted our second annual 5K Run, Roll, and Stroll (+Play) raising more than $5,500.

  • October 2025 - Provided $16,666 to the Baas and Qiang Labs at Drexel University to support priority SPG4 therapeutic development programs and sustain core research capacity.

  • December 2025 - Hosted our first annual winter fundraiser Play it Forward for a Cure on December 5 at National Harbor

  • December 2025 - Funded the maintenance of SPG4 large-animal (cattle) model to preserve this critical research resource and accelerate therapeutic development.

  • February 2025 - Fully funded a NULISA biomarker study at BCH to identify measurable disease markers that will support future clinical trials.

  • March 2026 - Hosted the 4th Annual Scientific Symposium on SPG4 in collaboration with Boston Children’s Hospital March 25-27 in Boston

Medical Advisory Board

  • Darius Ebrahimi-Fakhari, MD, PhD

    DIRECTOR, MOVEMENT DISORDERS PROGRAM AND ATTENDING, DEPARTMENT OF NEUROLOGY, BOSTON CHILDREN’S HOSPITAL; ASSISTANT PROFESSOR OF NEUROLOGY, HARVARD MEDICAL SCHOOL

    Dr. Ebrahimi-Fakhari is a child neurologist and neuroscientist with special expertise in childhood-onset neurogenetic, neurodegenerative, and movement disorders. His translational research includes The Registry and Natural History Study for Early-Onset Hereditary Spastic Paraplegia.


  • Ariane Soldatos, MD, MPH

    DIRECTOR, PEDIATRIC NEUROLOGY CONSULTATION SERVICE, NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) AND PHYSICIAN SCIENTISTS, UNDIAGNOSED DISEASES PROGRAM, NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI), NATIONAL INSTITUTES OF HEALTH (NIH)

    Dr. Soldatos' research interests include genomics and clinical trials for rare diseases. She is associate investigator on first-in-human clinical trials including gene therapy for rare childhood neurodegenerative diseases.

  • Matthew Elrick, MD, PhD

    ASSISTANT PROFESSOR OF NEUROLOGY, THE JOHNS HOPKINS HOSPITAL.

    Dr. Elrick specializes in the care of children with neuromuscular disorders, and EMG studies in children and adults. He has special interests in genetic neuromuscular and neurodegenerative disorders and Acute Flaccid Myelitis.







Liz Majewski

Board of Directors

Katie Gregg

Chris Lorek

Stephanie Lorek

Michael Gregg

Industry Partners

We work alongside leading organizations and advocacy networks to advance research, support families, and improve outcomes for those affected by rare diseases.

SPG4 Alliance Partners

What happens next depends on how quickly we move.

Your support accelerates progress toward real treatments for children with SPG4.